Patient Safety and Quality Assurance is 23.75% of the scored PTCE (the PTCB exam). Answer 10 exam style questions on MedWatch, VAERS and error reporting and see exactly which concepts would cost you points on test day.
Start the 10 questions →A patient has a serious adverse reaction to a prescription blood pressure medication. Which program is the FDA's system for voluntary reporting of this event?
These questions cover event reporting: MedWatch, event reporting: VAERS, event reporting: ISMP, near misses and sentinel events. Each one shows the correct answer and why every other option is wrong, so a miss tells you exactly what to review before the PTCE.
Prefer to read first? Every question from the practice set above, with the correct answer and why each wrong option is wrong.
Answer: D. MedWatch is the FDA's safety information and adverse event reporting program. Health professionals and consumers can report serious adverse events for drugs, biologics (other than vaccines), devices, and dietary supplements.
Why not A: VAERS is only for adverse events after vaccines.
Why not B: CSOS is the DEA's secure electronic ordering system for controlled substances (the electronic alternative to DEA Form 222). It is not an adverse event reporting program.
Why not C: A prescription drug monitoring program tracks controlled substance dispensing. It is not an adverse event system.
Exam tactic: MedWatch = FDA. Drugs, devices, supplements, product problems.
Answer: D. VAERS is co-managed by the Centers for Disease Control and Prevention (CDC) and the Food and Drug Administration (FDA).
Why not A: The DEA regulates controlled substances and does not run VAERS.
Why not B: CMS runs Medicare and Medicaid and does not co-manage VAERS.
Why not C: OSHA regulates workplace safety and does not co-manage VAERS.
Exam tactic: VAERS = CDC + FDA.
Answer: A. The ISMP National Medication Errors Reporting Program (MERP) is a voluntary, confidential program that collects error reports and shares lessons and prevention strategies with health care professionals.
Why not B: VAERS collects adverse events after vaccines, not general dispensing errors.
Why not C: Form 106 reports theft or significant loss of controlled substances.
Why not D: PDMPs track controlled substance dispensing, not medication errors.
Exam tactic: ISMP MERP = voluntary, confidential medication error sharing.
Answer: C. Near misses show where the process can fail. Reviewing them lets the pharmacy fix the cause before a similar error reaches a patient.
Why not A: The DEA one-business-day rule applies to theft or significant loss of controlled substances, not near misses.
Why not B: No federal law requires firing staff for near misses, and punishment discourages reporting.
Why not D: Near misses did not reach the patient and are not adverse drug reactions.
Exam tactic: Near miss = free lesson. Report it.
Answer: C. The Joint Commission defines a sentinel event as a patient safety event that results in death, permanent harm, or severe temporary harm. Sentinel events call for a comprehensive systematic analysis such as a root cause analysis.
Why not A: A near miss does not reach the patient. This error caused permanent harm.
Why not B: A side effect is an expected effect of a correctly used drug, not the result of an error.
Why not D: Therapeutic duplication is a DUR alert type, not a classification of harm.
Exam tactic: Death or permanent/severe harm = sentinel event = RCA.
Answer: A. RCA is a retrospective analysis that asks why the error happened at each level, focusing on processes and systems rather than blaming an individual, so the causes can be fixed.
Why not B: RCA focuses on systems, not blame. Seeking someone to punish discourages reporting.
Why not C: Cost is not the purpose of an RCA.
Why not D: RCA is an internal analysis. It is not a DEA report.
Exam tactic: RCA asks "why" until it reaches the system, not the person.
Answer: C. Failure mode and effects analysis (FMEA) is proactive: it looks for possible failures before they happen. RCA is retrospective and looks at an event that already occurred.
Why not A: RCA is retrospective. It analyzes an event that has already happened.
Why not B: DUR screens individual prescriptions for clinical problems, not processes.
Why not D: Medication reconciliation compares a patient's medication lists. It is not a process risk analysis.
Exam tactic: Before = FMEA (proactive). After = RCA (retrospective).
Answer: D. Continuous quality improvement (CQI) is an ongoing cycle of measuring performance, finding problems, making changes, and re-measuring.
Why not A: RCA examines one specific event in depth. It is not an ongoing monitoring cycle.
Why not B: DUR screens individual prescriptions for clinical issues.
Why not C: Prior authorization is an insurance approval process.
Exam tactic: Measure, change, re-measure, repeat = CQI.
Answer: C. An error that reached a patient needs immediate pharmacist involvement to assess risk, contact the patient and prescriber, and document the event per pharmacy policy.
Why not A: Contacting the patient about an error is coordinated by the pharmacist, who also assesses harm.
Why not B: Altering records to hide an error is never acceptable.
Why not D: Delay can allow harm. Errors must be addressed promptly.
Exam tactic: Error found? Pharmacist first, then documentation. Never hide it.
Answer: D. MedWatch accepts adverse event reports for dietary supplements as well as drugs, biologics, and devices.
Why not A: VAERS is only for adverse events following vaccination.
Why not B: Form 106 reports theft or loss of controlled substances.
Why not C: Form 41 records destruction of controlled substances.
Exam tactic: Supplements are FDA-regulated products: report to MedWatch.
The free 20 question diagnostic covers all 4 areas of the PTCE outline and shows the 3 fixes worth the most points.
Take the free diagnosticSee all 31 PTCB practice topics →